{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:16:38Z","timestamp":1777936598963,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician\u2019s office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.<\/jats:p>","DOI":"10.1177\/1352458513489601","type":"journal-article","created":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T01:52:25Z","timestamp":1370051545000},"page":"24-26","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing dalfampridine efficacy in the physician\u2019s office"],"prefix":"10.1177","volume":"20","author":[{"given":"JB","family":"Raffel","sequence":"first","affiliation":[{"name":"Department of Neurology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Centre for Neuroinflammation and Neurodegeneration, Imperial College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RS","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Centre for Neuroinflammation and Neurodegeneration, Imperial College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"key":"bibr1-1352458513489601","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000326213.89576.0e"},{"key":"bibr2-1352458513489601","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"bibr3-1352458513489601","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"bibr4-1352458513489601","unstructured":"Peripheral & Central Nervous System Drugs Advisory Committee Meeting. Fampridine-SR Tablets For Improvement in Walking Ability in Patients with Multiple Sclerosis. Federal Drug Administration, http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM185664.pdf (2011; accessed 1 March 2013)."},{"key":"bibr5-1352458513489601","unstructured":"European Medicines Agency. European public assessment report (EPAR) for Fampyra. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002097\/WC500109958.pdf (2011; accessed 1 March 2013)."},{"key":"bibr6-1352458513489601","unstructured":"Limmroth V, Putzki N, Goodman A. Data From Prolonged-Release Fampridine Trials Confirm that 20% Improvement in Walking Speed is Clinically Meaningful. http:\/\/www.posters2view.com\/ECTRIMS2011\/view.php?nu=476 (2011; accessed 1 March 2013_)."},{"key":"bibr7-1352458513489601","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S9046"},{"key":"bibr8-1352458513489601","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600411"},{"key":"bibr9-1352458513489601","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828cf7f3"},{"key":"bibr10-1352458513489601","unstructured":"Red Book. 114th ed. City: Thomson Reuters Healthcare, 2010, pp. 216: New York, USA."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458513489601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458513489601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458513489601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:37:39Z","timestamp":1777693059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458513489601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1177\/1352458513489601"],"URL":"https:\/\/doi.org\/10.1177\/1352458513489601","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}